David Stamler, M.D., Chief Executive Officer of Alterity,...

David Stamler, M.D., Chief Executive Officer of Alterity, commented, “We are excited to present
the Parkinson’s disease primate study to an international audience because we have shown that
ATH434 can reduce Parkinsonism in a higher order animal with symptoms that closely parallel
human disease. Importantly, the improvements in motor skills and general functioning that
parallel human parkinsonism were associated with reductions in abnormal iron in affected brain
regions, validating the approach we are using in our ongoing clinical trials. The data from this
study improve our ability to predict clinical outcomes and increases our confidence level in our
ongoing Phase 2 clinical trials in Multiple System Atrophy, a parkinsonian disorder with similar
underlying pathology to Parkinson’s disease.”